Table 13:
Evidence profile for roxadustat as an alternative to ESA for anemia in NDD-CKD patients
Recommendation for use in research setting only | This recommendation is evidence informed. |
Roxadustat should not be used for NDD-CKD patients, except in the context of an approved randomized controlled trial. The panel recommends conduct of large head-to-head multicentric randomized controlled trials in the South Asian region on NDD-CKD patients and measuring critically important outcomes (as elucidated in this guideline) such that evidence base for roxadustat is improved. |
ESA: Eythropoiesis-stimulating agents, NDD: Nondialysis dependent, CKD: Chronic kidney disease